Aroa Biosurgery Limited v. Controller General Of Patents, Designs And Trademarks and Anr

In the high-stakes world of medical biotechnology, a patent can be the difference between a breakthrough treatment reaching millions of patients or fading into obscurity. But what happens when the very institution tasked with granting those patents drops a bombshell rejection at the final hour—a ground never mentioned, never debated, never given a chance to be defended? For Aroa Biosurgery Limited, this wasn't a hypothetical. It was the reality that nearly killed its patent for an innovative tissue scaffold technology. This case is a masterclass in why procedural fairness is not just legal formality—it is the bedrock of any credible patent system.

Aroa Biosurgery Limited, a company working in the advanced field of regenerative medicine, filed a patent application for an invention titled 'Tissue Scaffolds Derived From Forestomach Extracellular Matrix.' This technology sat at the cutting edge of tissue engineering, aiming to use biological materials to support healing and reconstruction. Like every patent applicant, Aroa engaged with the patent examination process, expecting that any concerns about its application would be raised transparently during examination—typically through a First Examination Report (FER), where the applicant is given a formal opportunity to address objections. Instead, when the final order came, it delivered a fatal blow: a rejection on a ground that had never appeared anywhere in the prior proceedings.

Aroa Biosurgery's challenge was not about whether its invention was technically patentable. It was about something far more fundamental: fairness. The petitioner argued that the Controller General of Patents had introduced a fresh ground of rejection under Section 3(i)—a provision dealing with non-patentability—only at the final order stage. This meant Aroa was given no opportunity during the examination phase to amend its claims, present arguments, or submit evidence to overcome this objection. On the other side, the patent authorities defended the order, but the legal friction was clear: a party cannot meaningfully defend itself against an objection it never knew existed. The case turned into a contest over whether the patent office had honored the principles of natural justice—the ancient legal guarantee that no person should be condemned without a hearing.

The Calcutta High Court sided with Aroa Biosurgery. The court found that the impugned order suffered from two critical defects: first, it introduced a ground of rejection under Section 3(i) that was never raised during the examination process, stripping the applicant of any real chance to respond; and second, the order itself lacked adequate reasons, failing to explain the basis for its conclusion. Holding that the principles of natural justice had been violated, the court allowed the appeal and remanded the matter back to the Controller General of Patents for a fresh hearing on the merits. The outcome was mixed in the sense that the technical patentability question remained unresolved, but the procedural victory was decisive—Aroa got another chance to make its case, this time with the rules of fairness intact.

For founders, startup leaders, and IP professionals, this case delivers a powerful lesson: the patent examination process is not just about the science of your invention—it is about the procedure that surrounds it. Any ground for rejection must be raised during the examination phase, giving the applicant a genuine opportunity to respond, amend, or argue. A final order that ambushes an applicant with new objections, or that fails to provide clear reasoning, is vulnerable to being set aside. When pursuing or defending a patent, document every communication, scrutinize every examination report, and never accept a rejection order at face value if it introduces new grounds or lacks reasons. Procedural fairness is not a technicality—it is your strongest shield when the system fails to play by its own rules.